Saturday, October 31, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 19, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Upstart Holdings, Inc.and Certain Officers – UPST

View original at globenewswire.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Upstart Holdings, Inc.and Certain Officers – UPST NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Upstart Holdings, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Upstart expected to generate Q4 2025 revenue of approximately $288 million

    60% confidence
  • Defendants made materially false and misleading statements regarding Upstart's business, operations, and prospects: (i) Model 22 frequently overreacted to negative macroeconomic signals in its risk-separation processes; (ii) Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22's overly conservative assessment was having a significant negative impact on revenues, rendering FY 2025 guidance unreliable and/or unrealistic; (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times

    60% confidence
  • Upstart had knowingly calibrated its AI model to be more conservative on the credit side in earlier parts of Q3 2025, and that Model 22's overresponsiveness to macroeconomic signals would continue to negatively impact Q4 2025 revenues

    60% confidence
  • Upstart raised FY 2025 revenue guidance to approximately $1.01 billion, maintaining fee revenue guidance at approximately $920 million

    60% confidence
  • Upstart substantially raised FY 2025 revenue guidance to approximately $1.055 billion with fee revenue of approximately $990 million, attributing the increase to improvements in performance driven by Model 22

    60% confidence
  • Upstart issued FY 2025 financial guidance of approximately $1 billion total revenue and approximately $920 million in fee revenue

    60% confidence
  • Model 22 had overreacted to macroeconomic signals during Q3 2025, reducing borrower approvals and conversion rates and negatively impacting revenues

    60% confidence
  • Upstart's AI models more accurately quantify the true risk of a loan through risk separation, leading to higher approvals and lower interest rates relative to traditional lending practices and providing more predictable returns to capital partners including banks, credit unions, and institutional investors

    60% confidence
  • Upstart negatively revised its FY 2025 revenue guidance to approximately $1.035 billion and reduced fee revenue outlook to approximately $946 million from $990 million

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com